Systems pharmacology of mifepristone (RU486) reveals its 47 hub targets and network: Comprehensive analysis and pharmacological focus on FAK-Src-Paxillin complex

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Yu, Suhong ^a   Yang, Xingtian ^a   Zhu, Yewei ^a   Xie, Fangwei ^b   Lu, Yusheng ^a   Yu, Ting ^a   Yan, Cuicui ^a   Shao, Jingwei ^a   Gao, Yu ^a   Mo, Fan ^a   Cai, Guoneng ^a   Sinko, Patrick J ^c   Jia, Lee ^a  

^a FUZHOU UNIVERSITY   (China)

^b FUZHOU GENERAL HOSPITAL   (China)

^c Rutgers University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; MIFEPRISTONE; PAXILLIN; PROTEIN KINASE P60;

CELL ADHESION; CELL MOTION; CELL SURVIVAL; DRUG EFFECTS; GENE REGULATORY NETWORK; HUMAN; METABOLISM; TUMOR CELL LINE;

CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE REGULATORY NETWORKS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MIFEPRISTONE; PAXILLIN; PROTO-ONCOGENE PROTEINS PP60(C-SRC);

EID: 84923073622     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07830     Document Type: Article

References (50)

1. Herrmann,W. et al. Effects of an anti-progestin steroid in women: interruption of the menstrual cycle or early pregnancy (author's transl)]. Contracept Fertil Sex (Paris). 10, 389-393 (1982).
2. Chen, J. Z. et al. The Unique Pharmacological Characteristics of Mifepristone (RU486): from Terminating Pregnancy to Preventing Cancer Metastasis. Medicinal Research Reviews. 34, 979-1000 (2014).
3. Lalitkumar, S., Bygdeman, M. & Gemzell-Danielsson, K. Mid-trimester induced abortion: a review. Hum Reprod Update. 13, 37-52 (2007).
4. Winikoff, B. Acceptability of medical abortion in early pregnancy. Fam Plann Perspect. 27, 142-185 (1995).
5. Wu, J., Liang, Y.,Nawaz, Z. & Hyder, S. M. Complex agonist-like properties of ICI 182,780 (Faslodex) in human breast cancer cells that predominantly express progesterone receptor-B: implications for treatment resistance. Int J Oncol. 27, 1647-1659 (2005).
6. Sommer, P. et al.Glucocorticoid receptor over-expression promotes human small cell lung cancer apoptosis in vivo and thereby slows tumor growth. Endocrinerelated cancer. 17, 203-213 (2010).
7. Vladusic, E. A., Hornby, A. E., Guerra-Vladusic, F. K., Lakins, J. & Lupu, R. Expression and regulation of estrogen receptor beta in human breast tumors and cell lines. Oncol Rep. 7, 157-167 (2000).
8. Ramondetta, L. M. et al. Phase 2 trial of mifepristone (RU486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer. 115, 1867-1874 (2009).
9. Mei, L. et al. A novel mifepristone-loaded implant for long-term treatment of endometriosis: in vitro and in vivo studies. Eur J Pharm Sci. 39, 421-427 (2010).
10. Walker, K. J., Price-Thomas, J. M., Candlish, W.& Nicholson, R. I. Influence of the antioestrogen tamoxifen on normal breast tissue. Br J Cancer. 64, 764-768 (1991).
11. Llaguno-Munive, M.,Medina, L. A., Jurado, Romero-Pinã, M. & Garcia-Lopez, P. Mifepristone improves chemo-radiation response in glioblastoma xenografts. Cancer Cell Int. 13, 29 (2013).
12. Engman, M. et al. GSTM1 gene expression correlates to leiomyoma volume regression in response to mifepristone treatment. PLoS One 8, e80114 (2013).
13. Tieszen, C. R., Goyeneche, A. A., Brandhagen, B. N., Ortbahn, C. T. & Telleria, C. M. Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression.BMC Cancer. 11, 207 (2011)
14. Leong, S. P & Tseng, W. W. Micrometastatic cancer cells in lymph nodes, bone marrow, and blood: Clinical significance and biologic implications. CA Cancer J Clin. 64, 195-206 (2014).
15. Nguyen, D. X., Bos, P. D. & Massagué, J.Metastasis: from dissemination to organspecific colonization. Nat Rev Cancer. 9, 274-284 (2009).
16. Lu, Y. S. et al. Nitric Oxide Inhibits Hetero-adhesion of Cancer Cells to Endothelial Cells: Restraining Circulating Tumor Cells from Initiating Metastatic Cascade. Sci Rep. 4, 4344 (2014).
17. Wang, J. C. et al. Synthesis, spectral characterization, and in vitro cellular activities of metapristone, a potential cancer metastatic chemopreventive agent derived from mifepristone (RU486). AAPS J. 16, 289-298 (2014).
18. Berg, J. M., Rogers, M. E. & Lyster, P. M. Systems biology and pharmacology. Clin. Pharmacol. Ther. 88, 17-19 (2010).
19. Settles, B. ABNER: an open source tool for automatically tagging genes, proteinsand other entity names in text. Bioinformatics. 21, 3191-3192 (2005).
20. Smith, L. et al.Overview of BioCreative II gene mention recognition. Genome Biol. 9 Suppl 2, S2 (2008).
21. Morgan, A. A. et al. Overview of BioCreative II gene normalization. Genome Biol. 9 Suppl S3, (2008).
22. Bauer, S., Robinson, P. N. & Gagneur, J. Model-based gene set analysis for Bioconductor. Bioinformatics. 27, 1882-1883 (2011).
23. Dahlquist, K. D., Salomonis, N., Vranizan, K., Lawlor, S. C. & Conklin, B. R. GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. Nat Genet. 31, 19-20 (2002).
24. Ogata, H., Goto, S., Fujibuchi, W. & Kanehisa, M. Computation with the KEGG pathway database. Biosystems. 47, 119-128 (1998).
25. Mewes, H. W., Albermann, K., Heumann, K., Liebl, S. & Pfeiffer, F. MIPS: a database for protein sequence, homology data and yeast genome information. Nucleic Acids Res. 25, 28-30 (1997).
26. Hooper, S. D., & Bork, P. Medusa: a simple tool for interaction graph analysis. Bioinformatics. 21, 4432-4433 (2005).
27. Jia, L., Wong, H., Wang, Y., Garza, M., & Weitman, S. D. Carbendazim: disposition, cellular permeability, metabolite identification, and pharmacokinetic comparison with its nanoparticle. J Pharm Sci. 92, 161-72 (2003).
28. Wang, K., Li, M. & Bucan, M. Pathway-based approaches for analysis of genomewide association studies. Am J Hum Genet. 81, 1278-1283 (2007).
29. Chabbert-Buffet, N.,Meduri, G., Bouchard, P. & Spitz, I. M. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update. 11, 293-307 (2005).
30. Hernández, J. et al. Metallothionein induction by restraint stress: role of glucocorticoids and IL-6. Cytokine. 12, 791-796 (2000).
31. Tayel, S. S. et al. Progesterone suppresses interferon signaling by repressing TLR-7 and MxA expression in peripheral blood mononuclear cells of patients infected with hepatitis C virus. Arch Virol. 158, 1755-1764 (2013).
32. Shibata, M. et al. Glucocorticoids enhance Toll-like receptor 2 expression in human keratinocytes stimulated with propionibacteriumacnes or proinflammatory cytokines. J Invest Dermatol. 129, 375-382 (2009).
33. Jang, J. H. et al. RU486, a glucocortcoid receptor antagonist, induces apoptosis in U937 human lymphoma cells through reduction in mitochondrial membrane potential and activation of p38 MAPK. Oncol Rep. 30, 506-512 (2013).
34. Meyer, G., Leipprandt, J., Xie, J., Aupperlee, M. D. & Haslam, S. Z. A potential role of progestin-induced laminin-5/a6-integrin signaling in the formation of side branches in the mammary gland. Endocrinology. 153, 4990-5001 (2012).
35. Ebrahem, Q., Minamoto, A., Hoppe, G., Anand-Apte, B. & Sears, J. E. Triamcinolone acetonide inhibits IL-6 and VEGF-induced angiogenesis downstream of the IL-6 and VEGF receptors. Invest Ophthalmol Vis Sci. 47, 4935-4941 (2006).
36. Zhou, R. et al. Blockage of progesterone receptor effectively protects pancreatic islet beta cell viability. Steroids. 78, 987-995 (2013).
37. Schreiber, G. & Walter, M. R. Cytokine-receptor interactions as drug targets. Curr Opin Chem Biol. 14, 511-519 (2010).
38. Eid, M. A., Lewis, R. W. & Kumar, M. V. Mifepristone pretreatment overcomes resistance of prostate cancer cells to tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL). Mol Cancer Ther. 1, 831-840 (2002).
39. Verhoog, N. J., Du-Toit, A., Avenant, C. & Hapgood, J. P. Glucocorticoidindependent repression of tumor necrosis factor (TNF) alpha-stimulated interleukin (IL)-6 expression by the glucocorticoid receptor: a potential mechanism for protection against an excessive inflammatory response. J Biol Chem. 286, 19297-19310 (2011).
40. Hyder, S. M., Chiappetta, C., Stancel, G. M. Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells. Int J Cancer. 92, 469-473 (2001).
41. Herbst, R. S. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 59, 21-26 (2004).
42. Zhou, Y. et al. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res. 66, 404-411 (2006).
43. Grasso, A. W. et al. ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene. 15, 2705-2716 (1997).
44. Ewing, T. M. et al. Regulation of epidermal growth factor receptor by progestins and glucocorticoids in human breast cancer cell lines. Int J Cancer. 44, 744-752 (1989).
45. Hernández-Hernández, O. T., González-Garc?á, T. K. & Camacho-Arroyo, I. Progesterone receptor and SRC-1 participate in the regulation of VEGF, EGFR and Cyclin D1 expression in human astrocytoma cell lines. J Steroid Biochem Mol Biol. 132, 127-134 (2012).
46. Janneau, J. L. et al. Transcriptional expression of genes involved in cell invasion and migration by normal and tumoral trophoblast cells. J Clin EndocrinolMetab. 87, 5336-5339 (2002).
47. Ferretti, C., Bruni, L., Dangles-Marie, V., Pecking, A. & Bellet, D. Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Hum Reprod Update. 13, 121-141 (2007).
48. Tcacencu, I. Mifepristone (RU-486) impairs post-surgical wound healing of the larynx. Med. Sci. Monit. 8, BR397-400 (2002).
49. Brandhagen, B. N. et al. Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamics. BMC Cancer. 13, 35 (2013).
50. Parri, M. & Chiarugi, P. Rac and Rho GTPases in cancer cell motility control. Cell Commun Signal. 8, 23 (2010).